GlassScriptPhysician profile
Sarah E Fletcher
NPI 1730316902
$4,261.23
in general payments reported to CMS, 2019-2025
29 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,634 · 2020: $120 · 2021: $897 · 2022: $126 · 2023: $344 · 2024: $751 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197 · Travel and Lodging: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.23 |
| Travel and Lodging | $286.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paragon 28, INC. | $1,054.56 | 2019 | |
| Treace Medical Concepts, INC. | $746.58 | 2021 | |
| Medical Device Business Services, INC. | $405.77 | 2024 | |
| Smith+Nephew, INC. | $276.13 | 2019-2025 | Grafix, Bone Anchors With Arthroscopic Delivery System, Collagenase Santyl |
| Horizon Therapeutics Plc | $230.40 | 2019-2022 | |
| Rikco International, LLC | $201.98 | 2019 | |
| Averitas Pharma INC. | $158.37 | 2023-2025 | Qutenza |
| Paratek Pharmaceuticals, INC. | $153.65 | 2022-2025 | Nuzyra |
| Zyla Life Sciences, INC. | $136.96 | 2019-2020 | |
| Polynovo North America LLC | $122.04 | 2024-2025 | Novosorb Btm |
| Melinta Therapeutics, LLC | $114.11 | 2019-2024 | Orbactiv, Kimyrsa |
| Ibsa Pharma INC. | $100.33 | 2023-2024 | Tirosint, Licart, Licart |
| Organogenesis INC. | $97.81 | 2024-2025 | Affinity, Nushield, Puraply Am |
| Pfizer INC. | $77.60 | 2020 | |
| Integra Lifesciences Corporation | $72.98 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $57.24 | 2024-2025 | Activ.A.C., V.A.C. Veraflo Cleanse Choice |
| Amgen INC. | $26.33 | 2025 | Krystexxa |
| Biowound Solutions, INC. | $22.93 | 2025 | Bio-Connekt |
| Vertex Pharmaceuticals Incorporated | $22.92 | 2024 | |
| Cardiovascular Systems INC. | $22.73 | 2023 | |
| Kerecis Limited | $21.47 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Grt US Holding, INC. | $20.80 | 2022 | |
| Zimmer Biomet Holdings, INC. | $20.60 | 2021 | |
| Medtronic, INC. | $20.46 | 2024 | Venaseal |
| Nevro Corp. | $19.44 | 2022 | |
| Ossur Americas, INC. | $18.23 | 2025 | |
| Reprise Biomedical, INC. | $15.17 | 2024 | Miro3d |
| Orthofix Medical, INC. | $11.95 | 2022 | |
| Merck Sharp & Dohme LLC | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Fletcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.